# A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

> **NCT04641962** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 34 (actual)

## Conditions studied

- Primary Mitochondrial Myopathy

## Interventions

- **DRUG:** Bocidelpar
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04641962
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-24
- **Primary completion:** 2024-05-08
- **Final completion:** 2024-05-08
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Due to failure to meet the pre-specified criteria for efficacy
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641962, "A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04641962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*